ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
This marks a meaningful step in the company's continued expansion in the region
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Subscribe To Our Newsletter & Stay Updated
